MAYTANSINE

MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.

Cross Reference

Introduction

To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with MAYTANSINE?

MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with MAYTANSINE

MeSH term MeSH ID Detail
Breast Neoplasms D001943 24 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Melanoma D008545 69 associated lipids
Brain Diseases D001927 27 associated lipids
Leukemia P388 D007941 43 associated lipids
Per page 10 20 | Total 17

PubChem Associated disorders and diseases

What pathways are associated with MAYTANSINE

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with MAYTANSINE?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with MAYTANSINE?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with MAYTANSINE?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with MAYTANSINE?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with MAYTANSINE?

Xenograft Model

Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with MAYTANSINE

Download all related citations
Per page 10 20 50 100 | Total 611
Authors Title Published Journal PubMed Link
Watanabe J et al. Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer. In Vivo pmid:28438884
Yardley DA et al. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study. Cancer J pmid:26389758
Muzaffar M et al. Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine. Am J Ther pmid:25756468
pmid:
Hanka LJ and Barnett MS Microbiological assays and bioautography of maytansine and its homologues. 1974 Antimicrob. Agents Chemother. pmid:15825322
Mandelbaum-Shavit F et al. Binding of maytansine to rat brain tubulin. 1976 Biochem. Biophys. Res. Commun. pmid:985482
Sieber SM et al. Pharmacology of antitumor agents from higher plants. 1976 Cancer Treat Rep pmid:136296
Mugera GM and Ward JM Acute toxicity of maytansine in F344 rats. 1977 Cancer Treat Rep pmid:563288
Bhattacharyya B and Wolff J Maytansine binding to the vinblastine sites of tubulin. 1977 FEBS Lett. pmid:852577
Kupchan SM et al. The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. 1977 J. Org. Chem. pmid:874612
Hull RN et al. Studies on tissue culture produced plasminogen activator. I. Preliminary observations and the enhancing effect of colchicine and other antimitotic agents. 1977 Thromb. Res. pmid:18812
Wehrli W Ansamycins. Chemistry, biosynthesis and biological activity. 1977 Top Curr Chem pmid:74108
Osieka R et al. Chemotherapy of human colon cancer xenografts in athymic nude mice. 1977 Cancer pmid:144557
Wall ME and Wani MC Antineoplastic agents from plants. 1977 Annu. Rev. Pharmacol. Toxicol. pmid:326159
Higashide E et al. Ansamitocin, a group of novel maytansinoid antibiotics with antitumour properties from Nocardia. 1977 Dec 22-29 Nature pmid:593392
O'Connell MJ et al. Phase II trial of maytansine in patients with advanced colorectal carcinoma. 1978 Cancer Treat Rep pmid:356981
Issell BF and Crooke ST Maytansine. 1978 Cancer Treat. Rev. pmid:367597
Kupchan SM et al. Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids. 1978 J. Med. Chem. pmid:563462
Sieber SM et al. Teratogenic and cytogenetic effects of some plant-derived antitumor agents (vincristine, colchicine, maytansine, VP-16-213 and VM-26) in mice. 1978 Teratology pmid:694777
Johnson RK et al. Stathmokinetic and therapeutic effects of maytansine in mice bearing P388 and L1210 leukemias. 1978 Biochem. Pharmacol. pmid:708479
Eagan RT et al. Phase II evaluation of maytansine in patients with metastatic lung cancer. 1978 Cancer Treat Rep pmid:709559
Alabaster O and Cassidy M Flow microfluorometric analysis of P388 murine leukemia after administration of vincristine and maytansine in vivo. 1978 J. Natl. Cancer Inst. pmid:625068
Eagan RT et al. Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication. 1978 J. Natl. Cancer Inst. pmid:628025
Cabanillas F et al. Phase I study of maytansine using a 3-day schedule. 1978 Cancer Treat Rep pmid:348310
Chabner BA et al. Initial clinical trials of maytansine, an antitumor plant alkaloid. 1978 Cancer Treat Rep pmid:348311
Blum RH and Kahlert T Maytansine: a phase I study of an ansa macrolide with antitumor activity. 1978 Cancer Treat Rep pmid:348312
Blum RH et al. A therapeutic trial of maytansine. 1978 Cancer Clin Trials pmid:757139
Douros J and Suffness M New natural products of interest under development at the National Cancer Institute. 1978 Cancer Chemother. Pharmacol. pmid:86390
Donoso JA et al. Maytansine action on fast axoplasmic transport and the ultrastructure of vagal axons. 1978 Cancer Res. pmid:77186
Carter SK New drugs under clinical evaluation in the United States. 1978 Cancer Chemother. Pharmacol. pmid:155503
Tanida S et al. Inhibition of cilia regeneration of Tetrahymena by ansamitocins, new antitumor antibiotics. 1979 Antimicrob. Agents Chemother. pmid:475367
Rao PN et al. Cell cycle phase-specific cytotoxicity of the antitumor agent maytansine. 1979 Cancer Res. pmid:455300
Cabanillas F et al. Results of a phase II study of maytansine in patients with breast carcinoma and melanoma. 1979 Cancer Treat Rep pmid:371803
Ghetti B Induction of neurofibrillary degeneration following treatment with maytansine in vivo. 1979 Brain Res. pmid:581857
Maslin DN [Ansamycins]. 1979 Antibiotiki pmid:37801
Aldrich CD Pleiotropic phenotype of cultured murine cells resistant to maytansine, vincristine, colchicine, and adriamycin. 1979 J. Natl. Cancer Inst. pmid:224236
Chahinian AP et al. Phase I study of weekly maytansine given by iv bolus or 24-hour infusion. 1979 Nov-Dec Cancer Treat Rep pmid:526928
Creagan ET et al. Phase II evaluation of maytansine in patients with advanced head and neck cancer. 1979 Nov-Dec Cancer Treat Rep pmid:526939
Oki T Cytotoxic and antitumor antibiotics produced by microorganisms. 1980 Biotechnol. Bioeng. pmid:6159010
Ootsu K et al. Effects of new antimitotic antibiotics, ansamitocins, on the growth of murine tumors in vivo and on the assembly of microtubules in vitro. 1980 Cancer Res. pmid:6245801
Tanida S et al. Ansamitocin-induced synchrony in Tetrahymena pyriformis. 1980 J. Gen. Microbiol. pmid:6777454
Franklin R et al. A phase I-II study of maytansine utilizing a weekly schedule. 1980 Cancer pmid:7214295
Jaffrey IS et al. Response to maytansine in a patient with malignant thymoma. 1980 Cancer Treat Rep pmid:7379057
Tanida S et al. Ansamitocins, maytansinoid antitumor antibiotics. Producing organism, fermentation, and antimicrobial activities. 1980 J. Antibiot. pmid:7380728
Kim SU et al. Neurofibrillary degeneration in cultured adult mouse neurons induced by maytansine. 1980 Acta Neuropathol. pmid:7435167
Friedkin M and Rozengurt E The role of cytoplasmic microtubules in the regulation of the activity of peptide growth factors. 1980 Adv. Enzyme Regul. pmid:7039258
Neidhart JA et al. Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study. 1980 Apr-May Cancer Treat Rep pmid:7427953
Ahmann DL et al. Phase II study of maytansine and chlorozotocin in patients with disseminated malignant melanoma. 1980 Apr-May Cancer Treat Rep pmid:6448689
Rosenthal S et al. Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study. 1980 Oct-Nov Cancer Treat Rep pmid:7459897
Lin CM and Hamel E Effects of inhibitors of tubulin polymerization on GTP hydrolysis. 1981 J. Biol. Chem. pmid:6114958
Schrek R and Stefani SS Toxicity of microtubular drugs to leukemic lymphocytes. 1981 Exp. Mol. Pathol. pmid:7238845
Stebbings H and van Bueren J Stability of microtubules from insect ovarioles. 1981 Cell Biol. Int. Rep. pmid:7273149
Tanida S et al. Ansamitocin analogs from a mutant strain of Nocardia. I. Isolation of the mutant, fermentation and antimicrobial properties. 1981 J. Antibiot. pmid:7275830
Izawa M et al. Ansamitocin analogs from a mutant strain of Nocardia. II. Isolation and structure. 1981 J. Antibiot. pmid:7275831
Luduena RF and Roach MC Contrasting effects of maytansine and vinblastine on the alkylation of tubulin sulfhydryls. 1981 Arch. Biochem. Biophys. pmid:7305339
Schatten G and Schatten H Effects of motility inhibitors during sea urchin fertilization: microfilament inhibitors prevent sperm incorporation and restructuring of fertilized egg cortex, whereas microtubule inhibitors prevent pronuclear migrations. 1981 Exp. Cell Res. pmid:7308293
York J et al. Binding of maytansinoids to tubulin. 1981 Biochem. Pharmacol. pmid:7317106
Wang XF et al. [Studies on the antitumor constituents of Maytenus confertiflora Luo et Chen (Celastraceae). II. Isolation and characterization of maytansine and maytanprine from the stems]. 1981 Yao Xue Xue Bao pmid:7324964
Lin CM et al. Binding of maytansine to tubulin: competition with other mitotic inhibitors. 1981 Res. Commun. Chem. Pathol. Pharmacol. pmid:7255878
Nakahama K et al. Microbial conversion of ansamitocin. 1981 J. Antibiot. pmid:7333971
Izawa M et al. Demethylation of ansamitocins and related compounds. 1981 J. Antibiot. pmid:7333972
Izawa M et al. Hydroxylation of ansamitocin P-3. 1981 J. Antibiot. pmid:7333973
Baskin F et al. Correlation of double-minute chromosomes with unstable multidrug cross-resistance in uptake mutants of neuroblastoma cells. 1981 Proc. Natl. Acad. Sci. U.S.A. pmid:6943568
Ikeyama S and Takeuchi M Antitubulin activities of ansamitocins and maytansinoids. 1981 Biochem. Pharmacol. pmid:21043240
Edmonson JH et al. Phase II study of maytansine in advanced breast cancer. 1981 May-Jun Cancer Treat Rep pmid:7237478
Ono Y et al. Antitumor and cytocidal activities of a newly isolated benzenoid ansamycin, macbecin I. 1982 Gan pmid:6186564
Creech RH et al. Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578). 1982 Cancer Treat Rep pmid:6282460
Ratanatharathorn V et al. Phase II evaluation of maytansine in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group study. 1982 Cancer Treat Rep pmid:7093975
Hatano K et al. Biosynthetic origin of aminobenzenoid nucleus (C7N-unit) of ansamitocin, a group of novel maytansinoid antibiotics. 1982 J. Antibiot. pmid:7174527
Borden EC et al. Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas. 1982 Am. J. Clin. Oncol. pmid:6956236
Slavik M et al. Phase II studies in advanced, recurrent pelvic malignancies: conducted by the Gynecologic Oncology Group, Experimental Design and Experience. 1982 Am. J. Clin. Oncol. pmid:6897490
Perdue RE KB cell culture I. Role in discovery of antitumor agents from higher plants. 1982 Jul-Aug J. Nat. Prod. pmid:7130986
deVere White R et al. Maytansine as a cause of acute proliferative disorder of bladder urothelium in the rat. 1983 Cancer Treat Rep pmid:6825127
Thigpen JT et al. Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group study. 1983 Am. J. Clin. Oncol. pmid:6846245
Edmonson JH et al. Phase II study of maytansine in advanced sarcomas. 1983 Cancer Treat Rep pmid:6850657
Thigpen JT et al. Phase II study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. 1983 Am. J. Clin. Oncol. pmid:6869315
Ghetti B and Gambetti P Comparative immunocytochemical characterization of neurofibrillary tangles in experimental maytansine and aluminum encephalopathies. 1983 Brain Res. pmid:6354362
Fan YJ et al. [Use of 1,2:5,6-dianhydrogalactitol in combination with maytansine in experimental tumor therapy]. 1983 Yao Xue Xue Bao pmid:6677049
Sabio H et al. Maytansine in refractory childhood acute lymphocytic leukemia: a Pediatric Oncology Group study. 1983 Cancer Treat Rep pmid:6580069
Tsuruo T et al. Establishment and properties of vincristine-resistant human myelogenous leukemia K562. 1983 Gan pmid:6580255
Akimoto H et al. Chemical modification of ansamitocins. II. Synthesis of 3-epimaytansionoids via 3-maytansinones. 1984 Chem. Pharm. Bull. pmid:6437689
Kawai A et al. Chemical modification of ansamitocins. III. Synthesis and biological effects of 3-acyl esters of maytansinol. 1984 Chem. Pharm. Bull. pmid:6441645
Rebert CS et al. Effects of vincristine, maytansine, and cis-platinum on behavioral and electrophysiological indices of neurotoxicity in the rat. 1984 J Appl Toxicol pmid:6542922
Roach MC and Ludueña RF Different effects of tubulin ligands on the intrachain cross-linking of beta 1-tubulin. 1984 J. Biol. Chem. pmid:6480599
Niell HB et al. Effect of concentration and time of drug exposure on clonal growth of murine bladder cancer. 1985 Urology pmid:2579500
Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group. 1985 Cancer Treat Rep pmid:2859924
Fan YJ et al. [Effect of maytansine on the cell cycle of Ehrlich ascites carcinoma cells in mice]. 1985 Zhongguo Yao Li Xue Bao pmid:3158164
Ravry MJ et al. Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial. 1985 Am. J. Clin. Oncol. pmid:3834790
Gupta RS Species-specific differences in toxicity of antimitotic agents toward cultured mammalian cells. 1985 J. Natl. Cancer Inst. pmid:3855475
Fellous A et al. Effects of Tau and MAP2 on the interaction of maytansine with tubulin: inhibitory effect of maytansine on vinblastine-induced aggregation of tubulin. 1985 Cancer Res. pmid:3928146
Banerjee A et al. Interaction of reduced glutathione with bovine brain tubulin. 1985 Biochem. Biophys. Res. Commun. pmid:3994709
Huang AB et al. Maytansine inhibits nucleotide binding at the exchangeable site of tubulin. 1985 Biochem. Biophys. Res. Commun. pmid:4004859
Sato Y et al. Induction of neurofibrillary tangles in cultured mouse neurons by maytanprine. 1985 J. Neurol. Sci. pmid:4040155
Luduena RF et al. N,N'-Ethylene-bis(iodoacetamide) as a probe for structural and functional characteristics of brine shrimp, squid, and bovine tubulins. 1985 Can. J. Biochem. Cell Biol. pmid:4041960
Schibler MJ and Cabral FR Maytansine-resistant mutants of Chinese hamster ovary cells with an alteration in alpha-tubulin. 1985 Can. J. Biochem. Cell Biol. pmid:4041962
Duanmu C et al. Tubulin polymerization with ATP is mediated through the exchangeable GTP site. 1986 Biochim. Biophys. Acta pmid:3004597
Tsuruo T et al. Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. 1986 Cancer Res. pmid:3753552
Luduena RF et al. Interactions of vinblastine and maytansine with tubulin. 1986 Ann. N. Y. Acad. Sci. pmid:3460446
Takahashi M et al. Rhizoxin binding to tubulin at the maytansine-binding site. 1987 Biochim. Biophys. Acta pmid:3120782
Lacey E et al. Interaction of phomopsin A and related compounds with purified sheep brain tubulin. 1987 Biochem. Pharmacol. pmid:3606630